SYB-010 / Cancure Limited, Samyang Group - LARVOL DELTA

Samyang Biopharm USA, Inc. and Spanish National Research Council (CSIC) Announce Strategic Collaboration to Study SYB-010; A First-in-Class, Immune Stimulatory Monoclonal Antibody (GlobeNewswire) - “Samyang Biopharm USA, Inc…announced today that the company has entered into a research collaboration with the Spanish National Research Council (CSIC), a state agency for scientific research and technological development. The two organizations will work together to study the effect of NKG2D-ligand-containing vesicles and Samyang’s proprietary monoclonal antibody, SYB-010, on NKG2D receptor expression and NK cell function. Financial terms of the agreement were not released….Samyang continues to develop this antibody both internally and through collaborations to enable future clinical programs.”

Licensing / partnership • Oncology